Gastric Cancer
Copyright ©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Jul 14, 2006; 12(26): 4130-4136
Published online Jul 14, 2006. doi: 10.3748/wjg.v12.i26.4130
Figure 1
Figure 1 Alphastatin inhibit HUVECs migration induced by HGF( crystatl violet stain, × 100). All data shown as mean ± SD. aP < 0.05; bP < 0.01 vs control group.
Figure 2
Figure 2 Alphastatin has no effect on HUVECs proliferation.
Figure 3
Figure 3 Alphastatin inhibit HUVECs tubule formation in response to PMA. All data shown as mean ± SD. aP < 0.05 vs control group.
Figure 4
Figure 4 Expression of SPK , EDG-1, EDG-3, EDG-5 in HUVECs.
Figure 5
Figure 5 Alphastatin downregulate HUVECs SPK activity in a dose-dependent manner. HUVECs SPK activity reached a minimum value at 6 h. All data shown as mean ± SD. A: aP < 0.05; bP < 0.01 vs 0 nmol/L alphastatin; B: aP < 0.05 vs 0 h group.
Figure 6
Figure 6 Alphastatin inhibit new capillaries formation on Matrigel plug (original magnification × 100). A: Many newly formed capillaries full of red blood cells (arrow); B: Granuloma formation without significant neovasculature.
Figure 7
Figure 7 Factor-VIII staining revealed decreased blood vessel density in alphastatin-treated group vs PBS group (× 400).
Figure 8
Figure 8 Animals injected with alphastatin exhibited a significantly reduced tumor volume. All data shown as mean ± SD. aP < 0.05; bP < 0.01 vs PBS group.